Podrobno

Bidirectional modulation of TCA cycle metabolites and anaplerosis by metformin and its combination with SGLT2i
ID Harada, Makoto (Avtor), ID Adamski, Jerzy (Avtor), ID Wang-Sattler, Rui (Avtor), et al.

.pdfPDF - Predstavitvena datoteka, prenos (3,40 MB)
MD5: D7AD31308F6E0CF54B99FB0342215A65
URLURL - Izvorni URL, za dostop obiščite https://link.springer.com/article/10.1186/s12933-024-02288-x Povezava se odpre v novem oknu

Izvleček
Background: Metformin and sodium-glucose-cotransporter-2 inhibitors (SGLT2i) are cornerstone therapies for managing hyperglycemia in diabetes. However, their detailed impacts on metabolic processes, particularly within the citric acid (TCA) cycle and its anaplerotic pathways, remain unclear. This study investigates the tissue-specific metabolic effects of metformin, both as a monotherapy and in combination with SGLT2i, on the TCA cycle and associated anaplerotic reactions in both mice and humans. Methods: Metformin-specific metabolic changes were initially identified by comparing metformin-treated diabetic mice (MET) with vehicle-treated db/db mice (VG). These findings were then assessed in two human cohorts (KORA and QBB) and a longitudinal KORA study of metformin-naïve patients with Type 2 Diabetes (T2D). We also compared MET with db/db mice on combination therapy (SGLT2i + MET). Metabolic profiling analyzed 716 metabolites from plasma, liver, and kidney tissues post-treatment, using linear regression and Bonferroni correction for statistical analysis, complemented by pathway analyses to explore the pathophysiological implications. Results: Metformin monotherapy significantly upregulated TCA cycle intermediates such as malate, fumarate, and α-ketoglutarate (α-KG) in plasma, and anaplerotic substrates including hepatic glutamate and renal 2-hydroxyglutarate (2-HG) in diabetic mice. Downregulated hepatic taurine was also observed. The addition of SGLT2i, however, reversed these effects, such as downregulating circulating malate and α-KG, and hepatic glutamate and renal 2-HG, but upregulated hepatic taurine. In human T2D patients on metformin therapy, significant systemic alterations in metabolites were observed, including increased malate but decreased citrulline. The bidirectional modulation of TCA cycle intermediates in mice influenced key anaplerotic pathways linked to glutaminolysis, tumorigenesis, immune regulation, and antioxidative responses. Conclusion: This study elucidates the specific metabolic consequences of metformin and SGLT2i on the TCA cycle, reflecting potential impacts on the immune system. Metformin shows promise for its anti-inflammatory properties, while the addition of SGLT2i may provide liver protection in conditions like metabolic dysfunction-associated steatotic liver disease (MASLD). These observations underscore the importance of personalized treatment strategies.

Jezik:Angleški jezik
Ključne besede:anaplerosis, metabolic dysfunction-associated steatotic liver disease (MASLD), anti-inflammatory effects, metformin, pharmacometabolomics, SGLT2 inhibitors, TCA cycle, type 2 diabetes
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2024
Št. strani:14 str.
Številčenje:Vol. 23, art. 199
PID:20.500.12556/RUL-182278 Povezava se odpre v novem oknu
UDK:577:61
ISSN pri članku:1475-2840
DOI:10.1186/s12933-024-02288-x Povezava se odpre v novem oknu
COBISS.SI-ID:265262339 Povezava se odpre v novem oknu
Datum objave v RUL:06.05.2026
Število ogledov:231
Število prenosov:222
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Cardiovascular diabetology
Skrajšan naslov:Cardiovasc Diabetol
Založnik:Springer Nature
ISSN:1475-2840
COBISS.SI-ID:2595092 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Licenca:CC0 1.0, Creative Commons CC0 1.0 Univerzalna
Povezava:https://creativecommons.org/publicdomain/zero/1.0/deed.sl
Opis:CC Zero omogoča znanstvenikom, izobraževalcem, umetnikom in drugim ustvarjalcem ter lastnikom vsebin, zavarovanih z avtorsko pravico ali zbirko podatkov, da se odpovejo pravicam na svojih delih in jih tako čim bolj celovito predajo v javno domeno, da bodo drugi lahko prosto gradili, izboljševali in ponovno uporabljali dela za kakršne koli namene brez omejitev v skladu z zakonodajo o avtorskih pravicah ali zbirkah podatkov.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:anapleroza, steatozna bolezen jeter, povezana s presnovno disfunkcijo, protivnetni učinki, metformin, farmakometabolomika, zaviralci SGLT2, cikel TCA, sladkorna bolezen tipa 2

Projekti

Financer:Germany, Federal Ministry of Education and Research

Financer:Germany, Center for Diabetes Research

Financer:Germany, Federal Ministry of Education and Research
Številka projekta:0315494A
Naslov:Systems Biology of Metabotypes
Akronim:SysMBo

Financer:Germany, Helmholtz Alliance
Naslov:Imaging and Curing Environmental Metabolic Diseases
Akronim:ICEMED

Financer:Helmholz Zentrum München
Akronim:KORA

Financer:Drugi - Drug financer ali več financerjev
Program financ.:LMUinnovativ

Financer:(DFG) - German Research Foundation
Številka projekta:RA 459/3–1

Financer:EC - European Commission
Številka projekta:602936
Naslov:Identification and validation of novel pharmaceutical drug targets for cardiovascular disease
Akronim:CARTARDIS

Financer:EIT - European Institute of Innovation and Technology
Program financ.:Health Innovation Projects
Akronim:DeTecT2D

Financer:EIT - European Institute of Innovation and Technology
Program financ.:Health Innovation Projects
Akronim:iPDM-GO

Financer:EC - European Commission
Program financ.:H2020
Številka projekta:821508
Naslov:CARdiomyopathy in type 2 DIAbetes mellitus
Akronim:CARDIATEAM

Financer:EFPIA - European Federation of Pharmaceutical Industries and Associations

Financer:China, Ministry of Science and Technology
Številka projekta:G20200001507
Naslov:Multi-omics study and target identification of active components in traditional Chinese medicine and classical prescription components

Financer:Qatar Foundation
Program financ.:Biomedical Research Program

Financer:QNRF - Qatar National Research Fund
Številka projekta:NPRP11C-0115-180010

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj